292 related articles for article (PubMed ID: 19264769)
1. Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain.
Wu L; Zhou T; Yang ZY; Svehla K; O'Dell S; Louder MK; Xu L; Mascola JR; Burton DR; Hoxie JA; Doms RW; Kwong PD; Nabel GJ
J Virol; 2009 May; 83(10):5077-86. PubMed ID: 19264769
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.
Zhang MY; Xiao X; Sidorov IA; Choudhry V; Cham F; Zhang PF; Bouma P; Zwick M; Choudhary A; Montefiori DC; Broder CC; Burton DR; Quinnan GV; Dimitrov DS
J Virol; 2004 Sep; 78(17):9233-42. PubMed ID: 15308718
[TBL] [Abstract][Full Text] [Related]
3. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
Roben P; Moore JP; Thali M; Sodroski J; Barbas CF; Burton DR
J Virol; 1994 Aug; 68(8):4821-8. PubMed ID: 7518527
[TBL] [Abstract][Full Text] [Related]
4. Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1.
Nakamura GR; Byrn R; Wilkes DM; Fox JA; Hobbs MR; Hastings R; Wessling HC; Norcross MA; Fendly BM; Berman PW
J Virol; 1993 Oct; 67(10):6179-91. PubMed ID: 7690420
[TBL] [Abstract][Full Text] [Related]
5. Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.
Ingale J; Tran K; Kong L; Dey B; McKee K; Schief W; Kwong PD; Mascola JR; Wyatt RT
J Virol; 2014 Dec; 88(24):14002-16. PubMed ID: 25253346
[TBL] [Abstract][Full Text] [Related]
6. Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain.
Utachee P; Nakamura S; Isarangkura-Na-Ayuthaya P; Tokunaga K; Sawanpanyalert P; Ikuta K; Auwanit W; Kameoka M
J Virol; 2010 May; 84(9):4311-20. PubMed ID: 20164234
[TBL] [Abstract][Full Text] [Related]
7. Structural definition of a conserved neutralization epitope on HIV-1 gp120.
Zhou T; Xu L; Dey B; Hessell AJ; Van Ryk D; Xiang SH; Yang X; Zhang MY; Zwick MB; Arthos J; Burton DR; Dimitrov DS; Sodroski J; Wyatt R; Nabel GJ; Kwong PD
Nature; 2007 Feb; 445(7129):732-7. PubMed ID: 17301785
[TBL] [Abstract][Full Text] [Related]
8. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
Zwick MB; Kelleher R; Jensen R; Labrijn AF; Wang M; Quinnan GV; Parren PW; Burton DR
J Virol; 2003 Jun; 77(12):6965-78. PubMed ID: 12768015
[TBL] [Abstract][Full Text] [Related]
9. Structure of the Fab fragment of F105, a broadly reactive anti-human immunodeficiency virus (HIV) antibody that recognizes the CD4 binding site of HIV type 1 gp120.
Wilkinson RA; Piscitelli C; Teintze M; Cavacini LA; Posner MR; Lawrence CM
J Virol; 2005 Oct; 79(20):13060-9. PubMed ID: 16189008
[TBL] [Abstract][Full Text] [Related]
10. Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes.
Tanaka K; Kuwata T; Alam M; Kaplan G; Takahama S; Valdez KPR; Roitburd-Berman A; Gershoni JM; Matsushita S
Retrovirology; 2017 Sep; 14(1):44. PubMed ID: 28938888
[TBL] [Abstract][Full Text] [Related]
11. Isolation and characterization of a novel neutralizing antibody targeting the CD4-binding site of HIV-1 gp120.
Qiao Y; Man L; Qiu Z; Yang L; Sun Y; He Y
Antiviral Res; 2016 Aug; 132():252-61. PubMed ID: 27387828
[TBL] [Abstract][Full Text] [Related]
12. Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120.
Zwick MB; Parren PW; Saphire EO; Church S; Wang M; Scott JK; Dawson PE; Wilson IA; Burton DR
J Virol; 2003 May; 77(10):5863-76. PubMed ID: 12719580
[TBL] [Abstract][Full Text] [Related]
13. A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1.
Gach JS; Quendler H; Tong T; Narayan KM; Du SX; Whalen RG; Binley JM; Forthal DN; Poignard P; Zwick MB
PLoS One; 2013; 8(8):e72054. PubMed ID: 23991039
[TBL] [Abstract][Full Text] [Related]
14. Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120.
Kang CY; Hariharan K; Nara PL; Sodroski J; Moore JP
J Virol; 1994 Sep; 68(9):5854-62. PubMed ID: 7520095
[TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41.
Zhang MY; Yuan T; Li J; Rosa Borges A; Watkins JD; Guenaga J; Yang Z; Wang Y; Wilson R; Li Y; Polonis VR; Pincus SH; Ruprecht RM; Dimitrov DS
PLoS One; 2012; 7(9):e44241. PubMed ID: 22970187
[TBL] [Abstract][Full Text] [Related]
16. Near-Pan-neutralizing, Plasma Deconvoluted Antibody N49P6 Mimics Host Receptor CD4 in Its Quaternary Interactions with the HIV-1 Envelope Trimer.
Tolbert WD; Nguyen DN; Tehrani ZR; Sajadi MM; Pazgier M
mBio; 2021 Aug; 12(4):e0127421. PubMed ID: 34281393
[TBL] [Abstract][Full Text] [Related]
17. Structural elements of primary CCR5-using HIV-1 gp120 proteins influencing sensitivity and resistance to the broadly neutralizing monoclonal antibody b12.
Sterjovski J; Churchill MJ; Ellett A; Wesselingh SL; Ramsland PA; Gorry PR
Virology; 2012 Oct; 432(2):394-404. PubMed ID: 22818780
[TBL] [Abstract][Full Text] [Related]
18. Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region.
Wyatt R; Thali M; Tilley S; Pinter A; Posner M; Ho D; Robinson J; Sodroski J
J Virol; 1992 Dec; 66(12):6997-7004. PubMed ID: 1279195
[TBL] [Abstract][Full Text] [Related]
19. Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies.
Rathore U; Purwar M; Vignesh VS; Das R; Kumar AA; Bhattacharyya S; Arendt H; DeStefano J; Wilson A; Parks C; La Branche CC; Montefiori DC; Varadarajan R
J Biol Chem; 2018 Sep; 293(39):15002-15020. PubMed ID: 30093409
[TBL] [Abstract][Full Text] [Related]
20. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer.
Sattentau QJ; Moore JP
J Exp Med; 1995 Jul; 182(1):185-96. PubMed ID: 7540648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
